Introduction and overview of therapeutic apheresis

Journal of Clinical Apheresis

Volumn 25, Issue 5, 2010, Pages 240-249

  Okafor, Chidi ^a   Ward, David M ^b   Mokrzycki, Michele H ^c   Weinstein, Robert ^d   Clark, Pamela ^e   Balogun, Rasheed A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

apheresis; cytapheresis; plasmapheresis

Indexed keywords

APHERESIS; CYTAPHERESIS; PLASMAPHERESIS; REVIEW; TREATMENT INDICATION; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; DECISION MAKING; HUMAN; IMMUNOLOGY;

ABO BLOOD-GROUP SYSTEM; BLOOD COMPONENT REMOVAL; BLOOD TRANSFUSION; CYTAPHERESIS; DECISION MAKING; HUMANS; PLASMAPHERESIS;

EID: 78650014921     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20247     Document Type: Review

References (52)

1. Abel JJ, Rowntree LG, Turner BB,. Plasma removal with return of corpuscles (Plasmapheresis). J Pharmacol Exp Ther 1914; 5: 625-641.
2. Ward DM,. Therapeutic plasmapheresis and related apheresis techniques. In:, Petersdorf R, Martin JB, Adams RD, editors. Updates to Harrison's Principles of Internal Medicine. Philadelphia, PA: Williams and Wilkins. 1984. p 67.
3. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL,. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: 106-175. (Pubitemid 47025120)
4. George JN, Vesely SK, Terrell DR,. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-67. (Pubitemid 38057786)
5. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A,. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60: 1978-1980. (Pubitemid 36736017)
6. Koga M, Yuki N,. Campylobacter jejuni cst-II polymorphisms and association with development of Guillain-Barre syndrome. Neurology 2007; 69: 1727-1728.
7. Zignego AL, Giannini C, Monti M, Gragnani L,. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007; 39: S38-S45. (Pubitemid 47528193)
8. Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC,. Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 1979; 2: 824-827.
9. Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat G, Wernecke KD, Baumann G, Stangl K,. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646-652. (Pubitemid 34158161)
10. Kasner MT, Laury A, Kasner SE, Carroll M, Luger SM,. Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia. Am J Hematol 2007; 82: 1110-1112. (Pubitemid 350209857)
11. AMA/Specialty Society RVS Update Committee. AMA/Specialty Society RVS Update Committee Database 2009-VI. 2009.
12. Evidence-Based Medicine Working Group, Guyatt G, Cairns J, Churchill D, Cook D, Haynes B, Hirsh J, Irvine J, Levine M, Nishikawa J, Sackett D, Brill-Edwards P, Gerstein H, Gibson J, Jaeschke R, Kerigan A, Neville A, Panju A, Detsky A, Enkin M, Frid P, Gerrity M, Laupacis A, Lawrence V, Menard J, Moyer V, Mulrow C, Links P, Oxman A, Sinclair J, Tugwell P,. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992; 268: 2420-2425.
13. U.S. Congress, Office of Technology Assessment. Health Technology Case Study 23: The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis. U.S. Congress, Office of Technology Assessment. 1983. Online at.
14. Shumak KH, Rock GA,. Therapeutic plasma exchange. N Engl J Med 1984; 310: 762-771. (Pubitemid 14161409)
15. Council on Scientific Affairs. Current status of therapeutic plasmapheresis and related techniques. Report of the AMA panel on therapeutic plasmapheresis. JAMA 1985; 253: 819-825.
16. Klein HG, Balow JE, Dau PC, Hamburger MI, Leitman SF, Pineda AA, Tindall RS,. Clinical applications of therapeutic apheresis. Report of the Clinical Applications Committee, American Society for Apheresis. J Clin Apheresis 1986; 3:1- 92.
17. Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC,. An overview of current management. J Clin Apher 1993; 8: 189-194. (Pubitemid 23360775)
18. McLeod BC,. Introduction to the third special issue: clinical applications of therapeutic apheresis. J Clin Apher 2000; 15: 1-5. (Pubitemid 30176810)
19. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL,. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007; 22: 96-105. (Pubitemid 47025119)
20. McLeod BC,. An approach to evidence-based therapeutic apheresis.[see comment]. J Clin Apher 2002; 17: 124-132. (Pubitemid 35192437)
21. Mokrzycki MH, Kaplan AA,: Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23: 817-827. (Pubitemid 24173565)
22. Norda R, Berseus O, Stegmayr B,. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apher Sci 2001; 25: 33-41. (Pubitemid 33070548)
23. Norda R, Stegmayr BG, Swedish Apheresis G,. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003; 29: 159-166. (Pubitemid 36993783)
24. Malchesky PS, Koo AP, Roberson GA, Hadsell AT, Rybicki LA,. Apheresis technologies and clinical applications: the 2002 international apheresis registry. Ther Apher Dial 2004; 8: 124-143. (Pubitemid 38796942)
25. Korach JM, Petitpas D, Paris B, Bourgeade F, Passerat V, Berger P, Chillet P, French Registry Group. Plasma exchange in France: Epidemiology 2001. Transfus Apher Sci 2003; 29: 153-157. (Pubitemid 36993782)
26. Rock G, Clark B, Sutton D, CAG, CAAN. The Canadian apheresis registry. Transfus Apher Sci 2003; 29: 167-177. (Pubitemid 36993784)
27. Stegmayr B, Ptak J, Wikstrom B,. World apheresis registry report. Transfus Apher Sci 2007; 36: 13-16. (Pubitemid 46341974)
28. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z,. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005; 9: 391-395. (Pubitemid 43943059)
29. Shemin D, Briggs D, Greenan M,: Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 2007; 22: 270-276. (Pubitemid 350013061)
30. Yeo FE, Bohen EM, Yuan CM, Sawyers ES, Abbott KC,. Therapeutic plasma exchange as a nephrological procedure: a single-center experience. J Clin Apher 2005; 20: 208-216.
31. Kaplan AA,. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52: 1180-1196.
32. Silberstein LE, Naryshkin S, Haddad JJ, Strauss JF, III,. Calcium homeostasis during therapeutic plasma exchange. Transfusion 1986; 26: 151-155. (Pubitemid 16139665)
33. Weinstein R,. Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. J Clin Apher 2001; 16: 210-211. (Pubitemid 34037611)
34. Weinstein R,. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apher 1996; 11: 204-210. (Pubitemid 27026598)
35. Kankirawatana S, Huang ST, Marques MB,. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. J Clin Apher 2007; 22: 265-269. (Pubitemid 350013060)
36. Vucic S, Davies L,. Safety of plasmapheresis in the treatment of neurological disease. Aust N Z J Med 1998; 28: 301-305. (Pubitemid 28322353)
37. H Laird J, Douglas K, Green R,: Heparin-induced thrombocytopenia type II: a rare but significant complication of plasma exchange. J Clin Apher 2006; 21: 129-131.
38. Sonawane S, Kasbekar N, Berns JS,: The safety of heparins in end-stage renal disease. Semin Dial 2006; 19: 305-310. (Pubitemid 44091705)
39. FDA. FDA Public Health Update: Recall of Heparin Sodium Injection and Heparin Lock Flush Solution (Baxter) 2008. FDA; 2008. Online at.
40. Apter AJ, Kaplan AA,. An approach to immunologic reactions associated with plasma exchange. J Allergy Clin Immunol 1992; 90: 119-124.
41. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N,. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001; 16: 134-138. (Pubitemid 32988801)
42. Stramer SL,. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007; 131: 702-707. (Pubitemid 46729528)
43. Pool M, McLeod BC,. Pyrogen reactions to human serum albumin during plasma exchange. J Clin Apher 1995; 10: 81-84.
44. Allon M,. Current management of vascular access. Clin J Am Soc Nephrol 2007; 2: 786-800.
45. Vascular Access Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48 (Suppl 1): S248-S273.
46. Lok CE, Thomas A, Vercaigne L,. Canadian Hemodialysis Catheter Working Group. A patient-focused approach to thrombolytic use in the management of catheter malfunction. Semin Dial 2006; 19: 381-390. (Pubitemid 44393560)
47. Little MA, Walshe JJ,. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 2002; 39: 86-91. (Pubitemid 34062500)
48. Oliver MJ, Mendelssohn DC, Quinn RR, Richardson EP, Rajan DK, Pugash RA, Hiller JA, Kiss AJ, Lok CE,. Catheter patency and function after catheter sheath disruption: a pilot study. Clin J Am Soc Nephrol 2007; 2: 1201-1206.
49. James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hemmelgarn BR, Alberta Kidney Disease Network. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008; 148: 596-605. (Pubitemid 351669133)
50. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO,. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant 2006; 21: 1024-1031.
51. Yeh JH, Chen WH, Chiu HC,: Complications of double-filtration plasmapheresis. Transfusion 2004; 44: 1621-1625.
52. Balogun RA, Sahadevan M, Sevigny J, Kaplan AA,. Impact of therapeutic plasma exchange on cyclosporine kinetics during membrane-based lipid apheresis. Am J Kidney Dis 2001; 37: 1286-1289. (Pubitemid 32525167)